KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)

А. Л. Клочихин, Robert I. Haddad, Amichay Meirovitz, Sufia Safina, Irene Braña, Christophe Le Tourneau, Ravindra Uppaluri,Nancy Y. Lee, Ezra E.W. Cohen, Rebecca D. Chernock, William H. Westra, Hong Liu, Burak Gümüşçü, Kimberly Benjamin, Douglas Adkins

European Journal of Surgical Oncology（2023）

引用 0|浏览58

暂无评分

摘要

Introduction: The randomized, open-label, phase 3 KEYNOTE-689 trial (NCT03765918) is designed to evaluate neoadjuvant pembrolizumab and adjuvant pembrolizumab plus SOC in previously untreated LA HNSCC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要